Reported 2 days ago
Incyte Corporation (NASDAQ:INCY) plans to generate an additional $1 billion in revenue by 2029 through the launch of four new products, as presented at the Goldman Sachs Global Healthcare Conference. Despite facing loss of exclusivity for its main drug, Jakafi, which grew 24% year-over-year in Q1 2025 mainly driven by demand, Incyte aims to expand its portfolio and increase revenue through innovative pharmaceuticals for various diseases, particularly cancer.
Source: YAHOO